Gluten Intolerance Treatment Market Size

  • Report ID: 5081
  • Published Date: Aug 01, 2024
  • Report Format: PDF, PPT

Gluten Intolerance Treatment Market Size

Gluten Intolerance Treatment Market size was valued at USD 740.35 Million in 2023 and is likely to cross USD 4.02 Billion by the end of 2036, registering more than 13.9% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of gluten intolerance treatment is estimated at USD 832.97 Million. The market growth is backed by the growing research on how to reverse gluten intolerance. This is resulting in the rise in clinical trials and the development of workable gluten intolerance treatments.

The rising incidence of gluten-related disorders (GRDs) and the rise in their global prevalence is predicted in about 5% of the population. The ingestion of the gluten proteins present in wheat, barley, and rye is considered the main cause of GRDs. GRDs refer to a group of conditions that are heterogeneous, reflecting their autoimmune, allergic, and non-autoimmune-allergic etiology. The increasing adoption of gluten intolerance treatment by people suffering from GRDs is will positively impact the growth of the market.


Gluten Intolerance Treatment Market
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5081
  • Published Date: Aug 01, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of gluten intolerance treatment is estimated at USD 832.97 Million.

The gluten intolerance treatment market size was valued at USD 740.35 Million in 2023 and is likely to cross USD 4.02 Billion by the end of 2036, registering more than 13.9% CAGR during the forecast period i.e., between 2024-2036. The growing prevalence of autoimmune, allergic, and non-autoimmune-allergic GRDs and the rising damage of gut flora are the major factors driving the market growth.

Asia Pacific region is projected to account for 25% revenue share by 2036, due to growing concern about gluten intolerance in the region.

Takeda Pharmaceutical Company Limited, ActoBio Therapeutics, Inc., Precigen, Inc., Calypso Biotech BV, ImmunogenX, Inc., Alvine Pharmaceuticals, Dr. Falk Pharma GmbH, ImmusanT, Inc., Zedira GmbH, FunZyme BioTechnologies S.A., Amyra Biotech AG
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample